Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country

Bauduer, Frédéric; Ducout, Louis; Dastugue, Nicole; Capdupuy, C.; Renoux, M

doi:10.1016/s0145-2126(97)00159-8

Cited by 20 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Male patients were slightly predominant in our study (male/female ratio 1.1: 1). In other studies, male/female ratios have varied from 1 to 2.43 [22,23] . We observed a female predominance in younger patients (under age 55 years; male/female ratio 0.7: 1), which may partially explain such a small male/female ratio in all MDS patients.…”

Section: Discussionmentioning

confidence: 99%

Demographic, Hematologic, and Clinical Features of Myelodysplastic Syndrome Patients: Results from the First Polish Myelodysplastic Syndrome Registry

et al. 2015

View full text Add to dashboard Cite

Epidemiological studies on myelodysplastic syndromes (MDS) in Middle-Eastern Europe are scarce. No data about the demographic, clinical, and laboratory features of Polish MDS patients have been published. The aim of this study was to assess the epidemiological data and toxic exposure of Polish MDS patients and their association with hematological parameters and clinical outcomes. For 15 months, 966 living MDS patients were enrolled at 24 centers (12 university and 12 community hospitals). Follow-up was conducted for the next 55 months. The percentage of patients older than 80 years (16%) was between the values for Eastern and Western countries. In patients younger than 55 years, a female predominance was observed (male/female ratio 0.70:1 vs. 1.29:1; p < 0.001). Female patients had higher platelet counts (160 × 10⁹/l vs. 111 × 10⁹/l; p < 0.001). Patients exposed to chemicals were younger than patients without such exposure; their median age at MDS diagnosis was 66 vs. 70 years (p = 0.037). Smokers had significantly lower hemoglobin concentrations (8.6 vs. 9.1 g/dl; p = 0.032) and lower platelet counts (99 × 10⁹/l vs. 137 × 10⁹/l; p < 0.001) than nonsmokers. We provide the first description of the characteristics of Polish MDS patients. Females predominated in the group aged <60 years and they had higher platelet counts. The course of the disease is affected by toxic exposure and smoking.

show abstract

Section: Discussionmentioning

confidence: 99%

Demographic, Hematologic, and Clinical Features of Myelodysplastic Syndrome Patients: Results from the First Polish Myelodysplastic Syndrome Registry

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Incidence rates of MDS in Europe have been reported to vary between 2.1/100,000 inhabitants in the UK during 1984–1986 [18], 3.2 in France (1980–1990) [9], 3.5 in South Thames (1999–2000) [10], 3.6 in Sweden (1978–1982) [19], 4.1 (1975–1990) [11] and 4.9 (1996–2005) [13] in Germany (Düsseldorf), 7.7 in the Basque country (1993–1996) [12], 8.1 in Spain (1994–1998) [14], 9.3 in Somerset, UK [20], and 12.6 in Bournemouth, UK (1981–1990) [6]. A recent study from Romania found a very low incidence of 0.3/100,000 [21].…”

Section: Discussionmentioning

confidence: 99%

The incidence of myelodysplastic syndromes in Western Greece is increasing

et al. 2013

View full text Add to dashboard Cite

Descriptive epidemiology of the myelodysplastic syndromes (MDS) is always interesting and may reveal time-dependent and geographical variations, as well as occupational exposure. Epidemiological data in Greece are not available by now. We have collected and analyzed medical records of all patients with a documented diagnosis of MDS, performed by an expert hematologist and/or hematopathologist, in the geographical area of Western Greece, during the 20-year period, defined between 1990 and 2009. We have then calculated and described demographic and clinical features of the diagnosed MDS patient population, and assessed the incidence and prevalence rates of MDS in Western Greece, during the above-mentioned period. A total of 855 patients with newly diagnosed MDS have been identified. Refractory anemia was the most common subtype in both FAB and WHO classification systems and in both genders. Del-5q and RARS were more commonly encountered among females, and the dysplastic subtype of chronic myelomonocytic leukemia among males. Trisomy 8 was the most common single cytogenetic abnormality. The crude mean annual incidence rate of MDS was 6.0 per 100,000 inhabitants aged ≥15 years old (all subtypes according to FAB), and it was 4.8 per 100,000 when CMML and RAEB-T were excluded. Crude incidence rate was higher in rural than in urban areas, but this finding was not confirmed after age standardization. Age-standardized mean annual incidence rate in men was 7.9/100,000 and in women 3.4/100,000. A continuously increasing incidence rate of MDS has been observed throughout the study period.

show abstract

“…1 Based on regional cancer surveys or hospital-based statistics, the incidence rates for MDS have been estimated at 1.0 to 12.6 per 100,000 individuals, which would translate to between 4000 and 50,000 new diagnoses in the United States each year. [5][6][7][8][9][10][11] The incidence of MDS increases with age, particularly after age 60 years. 7,10 The annual incidence rates range from 15.0 to 49.0 per 100,000 in individuals aged !70 years.…”

mentioning

confidence: 99%

“…[5][6][7][8][9][10][11] The incidence of MDS increases with age, particularly after age 60 years. 7,10 The annual incidence rates range from 15.0 to 49.0 per 100,000 in individuals aged !70 years. 8,9,11 The risk of MDS also appears to be greater in men than in women and is associated positively with age.…”

mentioning

confidence: 99%

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

Kantarjian

Giles

List

et al. 2007

Cancer

215

179

View full text Add to dashboard Cite

Thrombocytopenia and platelet dysfunction contribute to hemorrhagic complications in the myelodysplastic syndromes (MDS). Reliable data regarding the frequency and consequences of thrombocytopenia in MDS are lacking. An extensive literature review indicated that the prevalence of thrombocytopenia (platelets <100 3 10 9 /L) in MDS ranged from 40% to 65%; the median frequency of thrombocytopenia prior to any MDS therapy was 65% (range, 23-93% high-risk disease. Treatment-related thrombocytopenia was observed in studies that involved azacitidine, tipifarnib, decitabine, lenalidomide, sirolimus, and combination chemotherapy with idarubicin, cytarabine, and topotecan. The reported incidence of hemorrhagic complications in the literature ranged from 3% to 53%, and the frequency of hemorrhagic deaths ranged from 14% to 24%.At MDACC, 460 patients had a coded cause of death: hemorrhage as a contributory cause of death, 20%; hemorrhage as the only cause of death, 10%. Thrombocytopenia was common in MDS, and there was an increased prevalence in higher risk IPSS categories. Many approved and investigational MDS therapies caused or exacerbated preexisting thrombocytopenia. The incidence of severe bleeding in MDS was greater than reported in current guidelines. Cancer

show abstract

Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country

Cited by 20 publications

References 9 publications

Demographic, Hematologic, and Clinical Features of Myelodysplastic Syndrome Patients: Results from the First Polish Myelodysplastic Syndrome Registry

Demographic, Hematologic, and Clinical Features of Myelodysplastic Syndrome Patients: Results from the First Polish Myelodysplastic Syndrome Registry

The incidence of myelodysplastic syndromes in Western Greece is increasing

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

Contact Info

Product

Resources

About